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Abstract: Background: Chronic diseases adversely affect quality of life (QOL). The ketogenic diet (KD)
may improve the QOL. Objective: The aim of this systematic review was to summarize the available
evidence of randomized controlled trials (RCTs) to establish the effect of KD on the QOL in adults
with chronic diseases. Methods: Reporting followed PRISMA guidelines. We included randomized
controlled trials (RCTs) conducted on adults with chronic disease including an intervention group
that received KD and a control group, and where QOL was reported as outcome. We searched
PubMed, APA PsycInfo, EMBASE, the Cumulative Index to Nursing and Allied Health Literature
(CINAHL), the Cochrane Library, and Clinicaltrials.gov, and the references of the included articles
and previous relevant reviews, without language or time restrictions. We critically appraised included
studies and narratively synthesized their findings. Results: Nine RCTs were included. The risk
of bias was low, except of allocation concealment and blinding. In patients with cancer: one RCT
found an improvement in overall QOL, another reported improved physical component summary,
and one found no superiority of KD in all QOL domains. In patients with neurological disorders:
improved QOL was reported in Alzheimer’s disease patients, whereas no difference in mental and
physical health QOL was noted in patients with multiple sclerosis. In patients with obesity and type
II diabetes: one RCT reported superiority of energy-restricted KD in improving role functioning,
mental health, health perceptions, and pain compared with guideline-based diet, whereas in another
RCT, high and low carbohydrate diets achieved comparable improvements. Among patients with
knee osteoarthritis, no differences between KD and low-fat groups were noted. Dietary compliance
with the KD, reported in three studies, was shown to be high. Side effects were mostly noted during
the first weeks of intervention, and adverse events were not markedly different with KD and the
comparison diet. Conclusions: The evidence from RCTs investigating the effect of KD on QOL in
adults with chronic disease is inconclusive. The promising effect noted in some included studies and
the low rates of adverse events and side effects encourage future investigations in this regard.
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1. Introduction
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Chronic diseases are health conditions characterized by long-term physical and/or
mental impairments requiring lengthy periods of supervision and care [1,2]. Professional bodies vary in the use of the term chronic, in addition to the variation in the
diseases included under its umbrella [2,3]. According to the World Health Organization
(WHO), a chronic disease is defined as being of long duration, slow progression, and
non-transmissible [4].
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Quality of life (QOL) is a concept approachable at varying levels of generality and the
definitions are diverse [5]. It is the individuals’ insights of their position in life relative to
their goals and expectations [6], and its concept encompasses all domains of life including
the psychological, social, and economic well-being of individuals, and their relationships
to relevant features of the environment [7]. QOL is best understood as representing
the gap between one’s actual functional level and one’s ideal standard [8]. As strongly
associated with morbidity, disability, and mortality [9–11], chronic diseases affect the QOL
by threatening the physical and emotional well-being, and through the development of
chronic stress [12–14]. QOL is hence an important outcome in chronic health conditions [15],
complimenting the traditional evaluation of reducing morbidity and mortality [16].
Although there is no standardized definition of the ketogenic diet (KD) [17], it is
characterized in general by a reduction in carbohydrates (CHO) and relative increases in
the proportions of proteins and fats, enabling an increased utilization of ketones in the
body [18,19]. The main types of the KD include the traditional ketogenic diet (TKD) containing a fixed ratio by weight of fat to combined protein and CHO [20], the medium-chain
triglyceride (MCT) KD using MCT oil to provide around half the calories [21], and the
modified Atkins diet (MAD) [22]. The clinical importance of these diets began with their
successful use in the treatment of intractable childhood epilepsy [23]. Furthermore, ample
evidence supports the broader therapeutic actions and effectiveness of the use of these
diets in the improvement of some metabolic pathways such as cancer, type two diabetes
(T2D), cardiovascular diseases (CVDs), polycystic ovary syndrome (PCOS), and some
neurological disorders, leading to beneficial health effects [23–25]. However, there are still
some concerns regarding their potential adverse effects including micronutrient deficiencies, appetite reduction, nausea, constipation, fatigue, hyperlipidemia, and unintended
weight loss [19,23]. KD may improve the QOL by reducing chronic pain, inflammation, and
improving metabolic parameters through multiple mechanisms [26]. The ketone bodies
produced by the liver results in a greater production of ATPs with a potential increase
in available energy [27], reduction in the production of reactive oxygen species [28], and
inhibition of pro-inflammatory cytokine mediators [29], although conclusive evidence in
this regard is lacking.
The aim of this systematic review is to summarize the available evidence of randomized controlled trials (RCTs) to establish the effect of KD on the QOL in adults with
chronic diseases.
2. Materials and Methods
2.1. Review Design
This systematic review was conducted following a predefined protocol that was
registered at the OSF registries (DOI: 10.17605/OSF.IO/2MK5G). The reporting of the
literature searching component of the systematic review was conducted according to the
Preferred Reporting Items for Systematic reviews and Meta-Analyses literature search
extension (PRISMA-S) [30], and that of the systematic review according to the PRISMA
statement [31]. Ethical approval for this study was not required.
2.2. Criteria for Study Inclusion
The inclusion criteria were designed according to the Population, Intervention, Comparator, Outcome, and Study design (PICOS) principle. Accordingly, randomized controlled trials (RCTs) thath have been conducted on adults with chronic disease; including
an intervention group and received KD and a control group and assessed QOL as an
outcome were included. Regarding the population, although there is a large variation in
the use of the term “chronic disease” [32], studies reporting on chronic disease, defined
as a disease that is long in duration, has a slow progression, and is not passed from person to person [33] were included. Studies reporting on adult patients, as defined by the
investigators (e.g., aged > 18 years at baseline) were included. Regarding the intervention,
although there is no standardized definition of the KD, studies reporting on diets high
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in fat, low in CHO resulting in hyperketonemia [17] such as classical KD, medium-chain
triglyceride (MCT)-KD, and MAD were included. When the intervention was not specified
as a KD, an upper limit of 50 g of CHO per day or 10% energy from CHO [34] was retained
for inclusion. RCTs involving a co-intervention were included if both arms of the study
received the same co-intervention. Regarding the comparator, studies employing any other
type of diet (e.g., low fat diet, anti-inflammatory diet, high fiber diet, or a different form
of KD) were included. Regarding the outcome, studies reporting on QOL were included
irrespective of the definition adopted, nor of the assessment tool. Finally, regarding study
design, only RCTs were included, irrespective of blinding.
Studies were excluded if they were conducted on healthy adults, adults with acute
conditions, or on pediatric participants; were conducted on non-human species; were
non-randomized or non-controlled; or were reported on in non-original articles without
detailed empirical data such as posters, conference abstracts, book chapters, or reviews.
2.3. Search Strategy
The search strategy was validated by a medical librarian. The search involved two key
concepts: (1) KD and (2) QOL. For each concept, controlled vocabulary such as Medical
Subject Headings (MeSH) terms and keywords were mapped. Search terms included but
were not limited to quality of life or well-being, combined with keto or Atkins. PubMed,
APA PsycInfo via Ovid, EMBASE via Ovid, the Cumulative Index to Nursing and Allied
Health Literature (CINAHL) via EBSCO, the Cochrane Library, and Clinicaltrials.gov were
searched, without any language or publication date restriction. The literature search was
conducted on 16 October 2021 by one author (MA), and the electronic search strategy
run on Embase via Ovid and PubMed is available in Supplementary Material Table S1.
Bibliographies of the included articles and relevant reviews were also hand-searched for
eligible studies.
2.4. Study Selection
Two sets of authors (MA/FA; EG/DP) screened titles and/or abstracts retrieved by
the search independently and in duplicate, and identified studies that potentially met the
inclusion criteria. Then, the full texts of potentially eligible studies were retrieved and
assessed independently and in duplicate for eligibility. Study selection was conducted
following calibration exercises to ensure the validity of the process. Disagreements were
solved through discussions or, in the absence of a consensus, with a third reviewer.
2.5. Data Extraction
The same two pairs of authors (MA/FA; EG/DP) extracted data from eligible studies,
independently and in duplicate, using a data extraction form, and following a calibration
exercise to ensure the validity of the process. For all included articles, the authors extracted
the characteristics of the study, details of the population included (number of enrolled
patients, demographic characteristics, type of chronic disease), intervention (features of KD,
duration of intervention, compliance), comparator, and outcomes (QOL, adverse events,
and attrition. When studies were lacking information, original references were retrieved
for additional data on the design and results.
2.6. Quality Assessment
The same two pairs of authors (MA/FA; EG/DP) assessed the risk of bias of included
studies, independently and in duplicate, following the Cochrane criteria (sequence generation, allocation concealment, blinding of participants and outcome assessors, incomplete
outcome data, and selective outcome reporting) [35]. For each study, each potential source
of bias was graded as low, high, or unclear risk. Disagreements were solved through
consensus or with the help of a third reviewer.
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2.7. Data Synthesis
2.7. Data Synthesis
As a meta-analysis was not possible, the author provided a narrative synthesis of the
As a meta-analysis was not possible, the author provided a narrative synthesis of the
findings from the studies including the author-recorded characteristics of the study, defindings from the studies including the author-recorded characteristics of the study, details
tails of the population included, the intervention, the comparator, the assessment methods
of the population included, the intervention, the comparator, the assessment methods and
and tools as well as the study’s outcomes.
tools as well as the study’s outcomes.
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sisted of MCT-KD. The duration of intervention ranged between 12 weeks [38,40–42,44] and
12 months [37]. Achievement of ketosis was measured either by blood ketones [36,37,39–44],
mainly beta-hydroxybutyrate, or urinary ketones [36,39]; whereas only Strath et al. [44]
did not assess ketosis. The comparators varied between standard traditional diet [36,40],
energy-restricted, high CHO diet [37], the American Cancer Society diet [42], Diabetes
Canada diet [38], modified Paleolithic diet [43], low fat diet [44], and usual diet [41,43,44].
Only Martin McGill et al. [39] compared two forms of the KD: MCT-KD and the modified MKD.
QOL was assessed using a variety of tools including disease-specific questionnaires
such as the European Organization for Research and Treatment of Cancer current core questionnaire (EORTC QLQ-C30) [36,39,40], the Diabetes-39 questionnaire [37], the Multiple
Sclerosis Quality of Life-54 questionnaire [43], the Quality of Life in AD questionnaire [41],
and the Knee Injury and Osteoarthritis Outcome Score quality of life questionnaire [44] or
generic questionnaires such as the Medical Outcomes Study Short Form (SF) [38,42].
Table 1. Characteristics of the included studies.
First Author,
Year,
Country

Study
Population &
Type of Chronic
Disease

Augustus,
2021,
Trinidad and
Tobago
(Trinidad)
[36]

Stages 2 and 3
cancer patients,
receiving
chemotherapy or
radiation,
nonvegetarian,
on a CHO-based
diet (>40%)
I: n = 20; 16
completers
C: n = 20; 20
completers

Age; %Male

Duration

Intervention:
Features of
KD

Control

Isocaloric
Diets (arms)

Standard
traditional
diet

Not
specified by
study
protocol

Cointervention

Assessment
of Ketosis

Assessment
of QOL

None

Urinary
ketones: dip
stick test and
urine
analyzer

EORTC
QLQ-C30

None

Serum BHB:
SIRRUS
analyzer
Urinary
ketones:
strips

SF-12 (PCS
and MCS)

None

Blood BHB:
home kit

EORTC
QLQ-C30
and EORTC
QLQ-BR23

None

Urinary
ketones: dip
stick test
Blood
ketones:
home kit

EORTC QLQ
C30 and
BN20

Cancer

Cohen, 2018,
Birmingham
(USA) [42]

Women with
ovarian or
endometrial
cancer, BMI ≥
18.5 kg/m2
I: n = 37; 25
completers
C: n = 36; 20
completers

80 women with
locally advanced
or metastatic
breast cancer
Khodabakhshi,
receiving
2020, Tehran
chemotherapy
(Iran) [40]
for ≥12 weeks
I: n = 40; 30
completers
C: n = 40; 30
completers

MartinMcGill, 2020,
United
Kingdom
[39]

12 patients with
glioblastoma
planning to go
temozolomide
chemotherapy
and radiotherapy
MKD: n = 6; 1
completed 12
weeks; 1
completed 12
months
MCTKD: n = 6; 3
completed 12
weeks; 2
completed 12
months

Age: mean
(SD):
I:
49.80 ± 6.72
C:
51.80 ± 4.18

16 weeks

MKD: 7-day
cyclic altered
KD (≈10%
CHO (50 g),
15% Protein
(75 g), 75%
Fat (167 g);
2000 Kcal);
main source
of Fat: MCT

12 weeks

KD: 5%
CHO (≤20
g); 25%
Protein
(≤100 g);
70% Fat
(≤125 g)

ACS diet

Neither
group was
instructed to
alter total
energy
intake

12 weeks

6% CHO,
19% Protein,
20% MCT,
55% Fat

55% CHO,
15%
Protein,
30% Fat

Both diets
calculated to
be eucaloric

12 weeks
12 months

I1: MKD: 5%
CHO, 80%
Fat, 15%
Protein
I2: MCTKD:
10% CHO,
75% Fat (30%
from MCT
nutrition
product),
15% Protein

None

Not
specified by
study
protocol

%Male: NR

Age: mean
(SD):
I: 61.5 ± 8.5
C:
58.6 ± 11.7
%Male: 0%

Age Range:
18–70
I: 44.8 ± 8.4
C:
45.2 ± 15.0
%Male: 0%

Age Median:
57; Range:
44–66
%Male:
66.60%
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Table 1. Cont.
First Author,
Year,
Country

Study
Population &
Type of Chronic
Disease

Lee, 2020,
Iowa (USA)
[43]

15 patients with
relapsing
remitting
multiple sclerosis
or progressive
relapsingremitting
multiple sclerosis
(expanded
disability status
≥ 4.5)
KD: n = 5; 4
analyzed (1:
insufficient data)
MPD: n = 6
Usual diet: n = 4

Age; %Male

Duration

Intervention:
Features of
KD

Control

Isocaloric
Diets (arms)

Cointervention

Assessment
of Ketosis

Assessment
of QOL

Neurological disorders

Philips, 2021,
Hamilton
(New
Zealand)
[41]

26 patients with
Alzheimer
diseases BMI >
18.5 kg/m2
Phase 1
KD: n = 13; 11
completers
Usual diet: n = 13;
13 completers
Phase 2
KD: n = 13; 10
completers
Usual diet: n = 13;
13 completers

Age
Total: Range:
36–63
Mean (SD):
51.9 ± 9.5
KD:
51.8 ± 11.8
MPD:
50.3 ± 9.5
C:
54.5 ± 11.8

12 weeks

MCT-based
KD:
ketogenic
version of
the modified
Paleolithic
diet with
supplemental MCTs to
achieve a
daily goal of
70% of total
Kcal from
fat)

Modified
Paleolithic
diet
C: Usual
diet

Not
specified by
study
protocol

Pre-study
vitamins,
supplements,
and/or
medications

Plasma BHB:
NR

Multiple
Sclerosis
Quality of
Life-54

12 weeks:
I or C
10 weeks:
washout

58% Fat
(26% SFA,
32% nonsaturated),
29% Protein,
7% Fiber, 6%
net CHO by
weight

Usual diet
11% Fat
(3% SFA,
8% nonsaturated),
19%
Protein,
8% Fiber,
62% net
CHO by
weight

Not
specified by
study
protocol

Daily multivitamin

Serum BHB:
ketone blood
monitor

QOL-AD

%Male: 50%

Age
Total: Range:
57–79
Mean (SD):
69.8 ± 6.0
KD > Usual
diet: Range:
57–77
Mean(SD):
68.0 ± 5.4
Usual diet >
KD:
Range:
61–79
Mean(SD):
71.7 ± 6.2
%Male:
Total: 62%
KD > Usual
diet: 77%
Usual diet >
KD: 46%

Obesity and T2DM

Brinkworth,
2016,
Adelaide
(Australia)
[37]

Adults with
T2DM (HbA1c ≥
7.0% or taking a
diabetes
medication),
overweight and
obese (BMI:
26–45 kg/m2 )
I: n = 58; 41
completers
C: n = 57; 37
completers

Durrer, 2021,
Southern
British
Columbia
(Canada)
[38]

Adults with
T2DM, using
glucose-lowering
medication,
obese (BMI ≥ 30
kg/m2 )
I: n = 98; 78
completers (98
ITT)
C: n = 90; 60
completers (90
ITT)

Age Range:
35–68
Mean (SD)
I: 58 ± 72
C: 58 ± 7

12 months

Very-low
CHO,
high-fat diet:
14% CHO
(<50 g); 28%
Protein, 58%
Fat (35%
MUFA, 13%
PUFA, <10%
SFA)

HighCHO,
low-fat
diet: 53%
CHO; 17%
Protein;
<30% Fat
(15%
MUFA, 9%
PUFA,
<10% SFA)

For I and C:
∼30%
energy
restriction
(500–1000
Kcal/day)

60-min,
moderateintensity,
exercise: 3
days/week

Plasma BHB:
D-3 Hydroxybutyrate
kit

Diabetes-39

12 weeks

Low-CHO
energyrestricted
commercial
weight loss
plan supplemented with
whole foods
(<50 g CHO;
35–45 g Fat,
110–120 g
Protein;
850–1100
Kcal)

Information
conforming with
2013
Diabetes
Canada
Clinical
Practice
Guidelines

Not
specified by
study
protocol

None

Capillary
blood
ketones: NR

SF-20

%Male:
I: 64%
C: 51%

Age: mean
(SD):
I: 58 ± 11
C: 59 ± 8
%Male:
I: 44%
C: 43%
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Table 1. Cont.
First Author,
Year,
Country

Study
Population &
Type of Chronic
Disease

Age; %Male

Duration

Intervention:
Features of
KD

Control

Isocaloric
Diets (arms)

Cointervention

Assessment
of Ketosis

Assessment
of QOL

Not
measured

Knee Injury
and Osteoarthritis
Outcome
Score quality
of life

Knee Osteoarthritis

Strath, 2020,
Birmingham
(USA) [44]

21 adults with
knee
osteoarthritis
LCD: n = 8
LFD: n = 6
C: n = 7

Age Range:
65–75
Mean (SD)
LCD:
71.00 ± 3.12
LFD:
72.33 ± 1.97
C:
68.71 ± 7.11
%Male: LCD:
60%; LFD:
75%; C: 80%
(Completers:
LCD: 60%;
LFD: 100%;
C: 75%)

12 weeks

Kcal:
unlimited;
Fat:
unlimited;
CHO: 20 g;
Proteins:
100 g

LFD: Kcal:
800–1200;
Fat: 50–67
g; CHO:
unlimited;
Proteins:
100 g
C: Kcal,
Fat, CHO,
Proteins:
unlimited

No

None

ACS: American Cancer Society; BHB: B-Hydroxybutyrate; BMI: Body mass index; C: Control; CHO: Carbohydrate; EORTC QLQ-C30:
European Organization for Research and Treatment of Cancer current core; GHS: Global Health Status; HbA1c: Glycated hemoglobin; I:
Intervention; ITT: Intention to treat; KD: Ketogenic diet; LCD: Low-carbohydrate diet; LFD: Low fat diet; MCS: Mental component summary;
MCT: Medium chain triglycerides; MCTKD: Medium chain triglyceride ketogenic diet; MKD: Modified ketogenic diet; MPD: Modified
Paleolithic diet; MUFA: Monounsaturated fatty acids; NR: Not reported; PCS: Physical component summary; PUFA: Polyunsaturated fatty
acids; QOL: Quality of life; QOL-AD: Quality of Life in Alzheimer’s Disease; SD: Standard deviation; SF-12: Medical Outcomes Study Short
Form-12 Health Survey; SF-20: Medical Outcomes Study Short Form-20 Health Survey; SFA: Saturated fatty acids; T2DM: Type 2 diabetes
mellitus; WHO: World Health Organization.

3.3. Assessment of Risk of Bias
Results of the assessment of risk of bias of the included RCTs are detailed
in Figure 2. Risk of bias regarding sequence generation was low for all studies, expect for
Strath et al. [44]. Allocation was concealed in Brinkworth et al. [37], Durrer et al. [38], Khodabakhshi et al. [40], Martin-McGill et al. [39], and Philips et al. [41], and was unclear in the remaining trials [36–39]. Personnel were blinded only in the studies by Brinkworth et al. [37],
Lee et al. [43], and Philips et al. [41]. In general, risk of bias for blinding of outcome
assessment and completeness of outcome data was low. Finally, selective reporting was
suspected for the studies by Augustus et al. [36], Cohen et al. [42], Martin McGill et al. [39],
and Strath et al. [44].
3.4. Results of Included Studies
The findings from the included studies are summarized in Table 2 and detailed in
Supplementary Material Table S2. As shown in Table 2a, in patients with a diagnosis of
cancer, the evidence regarding the effect of KD on QOL was inconclusive [36,39,40,42]. Augustus et al. [36] found a significant improvement in overall QOL, whereas Cohen et al. [42]
reported improved QOL only at the level of physical component summary. In the study
conducted by Martin McGill et al. [39], quantitative results were limited to only three patients, favoring the MKD. Finally, Khodabakhshi et al. [40] found no significant differences
in the effects of KD and regular diet on all domains of QOL.
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difference in mental health and physical health QOL scores among the compared groups
in patients with multiple sclerosis.
Similarly, among patients with obesity and Type II diabetes [37,38], contradictory
results were noted. Durrer et al. [38] showed that a ketogenic, energy-restricted diet resulted in improved measures of role functioning, mental health, health perceptions, and
pain compared with a diet and lifestyle conforming with the Diabetes Clinical Practice
Guidelines, whereas Brinkworth et al. [37] found that both high and low CHO diets
achieved comparable improvements in QOL.
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Table 2. (a) Results of included studies. (b). Results of included studies.
(a)
First Author, Year

Effect on QOL

Conclusion
Cancer

Augustus, 2021 [36]

Mean change: I: +28 (Sig.); C: +0.6 (NS)
Sig. between-group difference over time; effect
size: 0.268 (medium)
Inverse association between urinary ketones and
QOL (b = −3.175, 95% CI = −5.723, −0.626)

Keto-adapted patients on a MKD had an
improvement in self-reported QOL over time
KD may improve QOL of cancer patients (not
inclusive of advanced stage cancer) compared
with patients on a standard traditional diet

Cohen, 2018 [42]

Sig. within-group increase in PCS in I (+11%); NS
change in C
Sig. between-group difference in adjusted PCS, NS
between-group difference in MCS
NS association between PCS or MCS and serum
BHB

In women with ovarian or endometrial cancer, a
KD does not negatively affect quality of life and
may improve physical function

Khodabakhshi, 2020
[40]

Mean difference (95% CI):
Physical functioning: 9.9 (−0.7, 20) (NS)
Role functioning: 8.9 (−6, 23) (NS)
Cognitive functioning: 5.5 (−8, 14)
Emotional functioning: 2 (−10, 14)
Social functioning 3.5 (−4.6, 5.9) (NS)
Global quality of life: 8.1 (−5.7, 3.3) (NS)

After adjusting baseline values and chemotherapy
status, NS differences in all domains of QOL
between I and C
KD diet combined to chemotherapy in patients
with breast cancer does not bring additional
benefit

Martin-McGill, 2020
[39]

Week 6 onward, GHS improved for the patient
following MKD and reduced for patients
following MCTKD

For retained patients at 12 months, GHS reduced
within the MCTKD group and improved in the
MKD group

Neurological disorders

Lee, 2020 [43]

NS between-group differences in mental health
and physical health

NS differences in mental health and physical
health QOL scores among groups
Suggested clinically sig. improvements in mental
health and physical health QOL with Modified
Paleolithic diet (change > 5)
Suggested clinically sig. decline in mental health
and physical health QOL with usual diet

Philips, 2021 [41]

Treatment effect (mean ± SD)
Phase 1: KD > Usual diet: +2.86 ± 4.64; Usual diet
> KD: −1.15 ± 5.41
Phase 2: KD > Usual diet: +0.31 ± 3.68; Usual diet
> KD: +3.03 ± 7.52
All patients: KD > Usual diet: +2.95 ± 6.12; Usual
diet > KD: −0.42 ± 4.60
Overall treatment effect: +3.37 ± 6.86 (Sig. change)

Patients on KD had improved QOL compared to
those on usual diet
High rates of retention and adherence are
achievable in applying a 12-week MKD to patients
with Alzheimer’s disease and adverse effects are
mild

Obesity and T2DM
Brinkworth, 2016 [37]

NS between-group differences in anxiety and
worry, social burden, sexual functioning, and
energy and mobility

In overweight and obese adults with T2DM, both
high and low CHO diets achieved comparable
improvements in QOL

Durrer, 2021 [38]

Treatment effect (95% CI):
Physical Functioning: 0.7 (−7.7, 9.9) *
Role Functioning: 13.6 (2.4, 26.3) *
Social Functioning: 6.1 (−2, 14.3) *
Mental Health: 6.9 (1.9, 12.7) *
Health Perceptions: 19.2 (13.2, 25.4) (NS)
Pain: −7.5 (−17.2, −0.1) *
(* a precise p-value could not be obtained)

In obese patients with T2DM, there was sig.
improvement in role functioning, mental health,
health perceptions, and pain with low-CHO
energy-restricted diet compared with the usual
diet

Nutrients 2021, 13, 4463

10 of 18

Table 2. Cont.
Knee Osteoarthritis

Strath, 2020 [44]

LCD: sig. withing-group change (≈−0.6)
LFD: sig. withing-group change (≈−0.2)
C: sig. withing-group change (≈−0.4)
NS time * diet interaction and NS differences
in LCD and LFD group after post hoc analysis

NS differences in LCD and LFD group were noted after
post hoc analysis

(b)
First Author, Year

Compliance

Ketosis

Adverse events/Side
effects

Attrition

I: side-effects related to
keto-adaptation (first
2–6 weeks; sig. reduced
6 weeks post
treatment): fatigue,
dizziness, reduced
energy
C:
headaches/migraines
Unable to determine
whether reduced
energy or fatigue are
attributed to I or by
natural progression of
the disease

I: 2% [n = 4: nausea and
vomiting related to I affecting
subjects’ palatability (n = 2);
inability to complete testing at
all follow-up times (n = 1);
mortality not related to
medical treatment nor I (n = 1)]
C: 0%

NR

I: n = 6 did not enroll due to
scheduling conflicts; n = 6
withdrew: 1 scheduling
conflicts; 1 no longer wishing
to comply with dietary
requirements; 3 cancer
recurrence; 1 death
C: n = 10 did not enroll due to
scheduling conflicts; n = 6
withdrew: 3 scheduling
conflicts; 2 no longer wishing
to comply with dietary
requirements, 1 death

None reported in both
groups

I: n = 10 withdrew after
beginning assigned diet (2
nausea and hypoglycemia; 3
weakness and hunger; 1
refusal to participate; 2 unable
to stick to diet; 2 lack of energy
and oiliness of the diet)
C: n = 3 patients withdrew
before beginning assigned diet;
n = 7 withdrew after beginning
assigned diet (5 frequent blood
sampling; 1 surgery; 1
diabetes)

Cancer

Augustus, 2021 [36]

Cohen, 2018 [42]

Khodabakhshi,
2020 [40]

Three-day food diaries
(2 weekdays and 1
weekend) obtained at
the weeks 6 and 12

Weekly phone
calls/emails from the
study dietitian to
review food records
and discuss strategies
to enhance participants’
adherence

BHB every 3 weeks and
dietary intake

Sig. rise in urinary
ketones in I vs. C

BHB (mmol/L)
I: Sig. increase
C: NS change

Serum ketones > 0.5
mmol/L: 66.7%
Sig. increase in
serum ketones in I

Nutrients 2021, 13, 4463

11 of 18

Table 2. Cont.

Martin-McGill, 2020
[39]

Assessment of diet
adherence: food diaries
Assessment of ketosis:
urinary ketones and
blood ketones (at
home)

Blood ketones: ≥4
mmol/L
During the first 6
weeks: MCTKD:
79.7%; MKD: 79.3%

Hypokalemia (n = 2),
hypernatremia (n = 1),
hypocalcemia (n = 1),
partial seizure (n = 1),
post-operative wound
infection (n = 1) seizure
(n = 1), back pain (n = 1)
[none related to the
dietary intervention]
Gastrointestinal side
effects:
First 6 weeks: MCT KD
group: diarrhea (n = 1),
nausea (n = 1),
vomiting (n = 1),
dyspepsia (n = 1); MKD
group: vomiting (n = 1)
and a dry mouth (n = 1)
At month 6: MCTKD:
diarrhea, dyspepsia,
constipation (n = 1);
MKD: constipation
(n = 1)

MCTKD: 6 randomized: 1
withdrew prior to commencing
(changed mind); 5 commenced;
2 withdrew (1 dietary burden;
1 recruited to another trial); 3
completed 12 weeks; 1
withdrew (GI intolerance); 2
completed 12 months
MKD: 6 randomized: 1
withdrew prior to commencing
(non-related SAE); 5
commenced; 4 withdrew (2
dietary burden; 1 tumor
progression; 1 nausea); 1
completed 12 weeks; 1
completed 12 months

Neurological disorders

Lee, 2020 [43]

Philips, 2021 [41]

Plasma BHB

Assessment of diet
adherence: 3-day (2
weekdays, 1 weekend
day) food record
Assessment of ketosis:
Bedtime ketone
monitoring

Plasma BHB: ≥0.50
mmol/L
Sig. higher BHB in
KD than MPD and
C

None reported

n = 1 in KD not analyzed
because of large amount of
missing data

Serum BHB ≥ 0.6
mmol/L
85.7% of patients
who completed KD
achieved sustained
physiological
ketosis

I: Increased irritability:
19%; Increased fatigue:
23%; Sugar craving: 8%;
Insomnia: 4%; Muscle
cramp: 12%;
Constipation: 4%;
Feeling light headed:
15%; Increased back
pain: 4%; Excessive
hunger: 8%; Excessive
thirst: 4%; Diarrhea:
4%; Palpitations: 4%
C: Increased irritability:
35%; Increased fatigue:
27%; Sugar craving:
23%; Insomnia: 19%;
Muscle cramp: 4%;
Constipation: 15%;
Feeling light headed:
12%; Increased back
pain: 12%; Nausea: 8%;
Headache: 12%; Heart
burn: 8%; Palpitations:
4%; Urinary calculus:
4%; Psychotic episode:
4%

Phase 1
I: n = 13; 2 withdrew (1
declined to remove daily sugar;
1 excess coconut oil and
diarrhea); 11 completers
C: n = 13; 13 completers
Phase 2
I: n = 13; 10 completers; 3
withdrew (1 declined to
remove daily sugar; 1 declined
to remove daily beer; 1
declined most of the food)
C: n = 13; 13 completers
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Table 2. Cont.
Obesity and T2DM

Brinkworth, 2016
[37]

Durrer, 2021 [38]

Good compliance in
both groups to
prescribed diets
throughout the study
assessed by dietary
intake

I: non-adherence: 2.12%
Assessment of food
intake: fasting blood
sample and a 3-day diet

Plasma BHB
increased more
with I after 4 weeks
and remained
higher over 52
weeks than C (Sig.)

Musculoskeletal
ailments: I: n = 8; C:
n = 13 [Associated with
exercise training: I:
n = 6; C: n = 8];
Gastrointestinal
disorders (constipation
and diverticulitis): I:
n = 2; C: n = 1,
Esophageal ulcers with
Helicobacter pylori
infection: C: n = 1;
Non-hospitalized
hypoglycemia incident:
I: n = 1; Hospitalization
for arrhythmia with
suspected heart failure:
C: n = 1; Prostate cancer
and melanoma: I: n = 1;
C: n = 1; Non-study
related workplace
injuries: I: n = 3; C:
n = 1; Hospitalization
for pneumonia: I: n = 1;
Malignant
hyperthermia: I: n = 1;
Anaphylactic reaction
to the influenza vaccine:
C: n = 1; Motor vehicle
accident: C: n = 1

NR

I: n = 4: mild
hypoglycemic events
(n = 2 when
participants were
reluctant to reduce
insulin dosages by the
recommended amount;
resolved with
recommended
medication);
Hypoglycemic
symptoms (n = 1 might
be due to waiting too
long between meals;
resolved after solving
this issue); Cardiac
event (n = 1 occurred 3
weeks into the study;
deemed not related to I
by data and safety
monitoring board)
C: n = 0

I: n = 17 (6 lost to follow-up; 4
time constraints; 3 work
commitments; 2 unable to
comply with diet; 2 personal
reasons; 1 health issue external
to study)
C: n = 21 (4 lost to follow-up; 1
time constraints; 3 work
commitments; 5 unable to
comply with diet; 5 personal
reasons; 3 health issue external
to study)

Drop-out prior to commencing
the trial:
I: n = 4 (1 ineligible; 3 lost
contact)
C: n = 15 (2 ineligible; 1 moved
away; 12 lost contact)
Attrition
I: n = 16 (2 family issues; 2
could not adhere; 2 unrelated
health issues; 1 travel; 9 lost
contact)
C: n = 15 (15 lost contact)
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Table 2. Cont.
Knee Osteoarthritis

Strath, 2020 [44]

Adherence verbally
confirmed; food
journals assessed by a
dietician and the study
administrator at each
visit

Not measured

NR

LFD: 1 lost to nonadherence
C: 2 failed to complete the
study

BHB: B-Hydroxybutyrate; C: Control; CHO: Carbohydrate; CI: Confidence interval; EORTC QLQ-C30: European Organization for Research
and Treatment of Cancer current core; GHS: Global Health Status; I: Intervention; KD: Ketogenic diet; LCD: Low-carbohydrate diet; LFD:
Low at diet; MCS: Mental component summary; MCT: Medium chain triglycerides; MCTKD: Medium chain triglyceride ketogenic diet;
MKD: Modified ketogenic diet; MPD: Modified Paleolithic diet; MUFA: Monounsaturated fatty acids; NR: Not reported; NS: Not significant;
PCS: Physical component summary; PUFA: Polyunsaturated fatty acids; QOL: Quality of life; SD: Standard deviation; SFA: Saturated fatty
acids; Sig: Significant; T2DM: Type 2 diabetes mellitus. * indicates interaction.

3.5. Dietary Compliance with the Ketogenic Diet
As Table 2b shows, the results of dietary compliance with the KD were reported
only in three studies [37,38,40]. Whenever investigated, good dietary compliance was
reported [37,38,40], reaching 98% in the study by Durrer et al. [38], and 96% in the study
by Khodabakhshi et al. [40]. Interestingly, in the latter study [40], only 66.7% of the group
had serum ketones above 0.5 mmol/L at 12 weeks.
3.6. Adverse Events
Adverse events were not investigated in the studies by Cohen et al. [42] and
Strath et al. [44]. In the studies conducted by Lee et al. [43] and Khodabakhshi et al. [40], no
adverse events of the KD were noted. In the study by Augustus et al. [36], side-effects were
mostly noted during the first two to six weeks, relating to the keto-induction phase, and they
consisted mainly of feelings of fatigue and dizziness. In the studies by Brinkworth et al. [37]
and Philips et al. [41], there were no marked differences in the adverse events between
patients receiving KD and those receiving the comparison diet. Details about the specific
side effects are reported in Table 2b.
4. Discussion
This systematic review explored the effect of KD on QOL among adults with chronic
disease. Overall, we could not find conclusive evidence about the effectiveness of the
different forms of the KD in improving QOL in this patient population. This finding is
limited by the divergent dietary regimens used for prescribing the KD, the heterogeneity
of the subjects in the studies, and chronic diseases assessed as well as the methodological
variations between studies such as a comparison, and the assessment methods of ketosis
and QOL.
All included publications were recent (2016–2021), reflecting increased attention to
KD in the scientific literature for health-related outcomes beyond those related to the
management of epilepsy [45]. The KD has been advocated for improving the QOL of
healthy and ill people due to several biologically plausible mechanisms. One suggested
theory is the effect of ketone bodies, specifically B-hydroxybutyrate, in inducing mild
euphoria [46]. Qualitative findings from the study by Martin-McGill et al. [39] illustrate
this, with patients reported “experiencing a fantastic quality of life” and describing the diet
as offering a sense of control whilst receiving their tumor treatment”. BHB has shared
actions with gamma-hydroxybutyrate (GHB) on the brain. GHB is a catabolite in the
brain of gamma-aminobutyrate (GABA), thus lowering cerebral energy requirements and
playing a neuroprotective role [47]. Another plausible theory could be the weight-loss effect
of the KD. Weight loss is suggested to improve health-related QOL; this relationship is
consistent with considerable loss such as the case after bariatric surgery [48]. Furthermore,
the potential positive effect of KD on QOL could be attributed to its anti-inflammatory
effect. It is hypothesized that excess dietary CHO contribute to oxidative stress, pain, and
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inflammation [44]. Chronic inflammation significantly predicts lower QOL in emotional
and relational measures [49,50].
Specifically, in cancer patients, the effects of the KD on QOL could be secondary to
its therapeutic effects. For example, an increasing number of preclinical studies suggest
the KD as a potent anticancer therapy because of its direct effects on tumor growth, which
may improve the overall health status of patients as well as their QOL [51,52]. In patients
with neurological disorders such as Alzheimer’s disease, although the literature is scarce
and lacks scientific rigor, KD seems to improve the cognitive symptomatology of these
diseases, hence its speculated effect on QOL in this patient population [53]. The possible
neuroprotective effects of the KD could potentially reside in its beneficial effect on reducing
accumulation of amyloid plaques, protecting against amyloid-beta toxicity, and through
the modification of the neuronal network activity, although precise mechanisms remain
unknown. Furthermore, BHB has cellular signaling functions [54] that broadly link the
outside environment to cellular function through epigenetic gene regulation, with potential
implications on human aging [55]. Finally, the KD diet is reportedly associated with
improvements in food cravings, increased levels of physical activity, sleep, and sexual
function, and decreased medication need [45,56]. These effects may be of utmost interest to
type 2 diabetic patients.
The scientific literature highlights the lack of a standardized definition of the KD.
Commonly, this diet is characterized by a reduction in CHO below 10% of daily energy
intake or typically 30 to 50 g of CHO per day, and a relative increase in fat intake, with a
fat-to-CHO and protein intake ratio of 3:1 to 4:1 [57]. The included studies in this systematic
review varied in their definition of the KD, the level of CHO restriction as well as protein
and fat intakes, in addition to the inclusion of MCT as a source of fat. Furthermore, the use
of KD and induction of ketosis were not explicit in some included studies, nevertheless,
the features of the interventional diet were in accordance with that of a KD.
There was also a variation in the definition of physiological ketosis with different
cut-off values used in different studies as well as the assessment of ketosis, varying between
blood and urinary ketones. Specifically, regarding the latter method, urinary ketones were
used to monitor the diet in numerous studies [36,39,42]. Urinary ketones may not be robust
markers of compliance, as they can be affected by hydration status, some medications or
substances such as vitamin C. Furthermore, the reading is an average of urine ketone levels
since the last void. Finally, some kits only measure acetoacetic levels and others have a
short shelf-life [56]. Of interest, apparently low urinary ketones may discourage patients
when they are adhering to the diet robustly [39]; this is to be considered for future RCTs
investigating the KD. In addition, only the two studies conducted by Augustus et al. [36]
and Cohen et al. [42] reported on the relationship between ketone bodies and QOL. The
results of the two studies were contradictory: while the first reported an inverse association
between urinary ketones and QOL, the latter reported no association between physical nor
mental health and serum BHB, hence a conclusion on this relationship cannot be drawn.
Importantly, participant blinding was impossible in all trials. It is thus likely that improvements noted with the KD may be biased by the increased attention given to patients
through consultations, education, and follow-up, and by the fact that patients had the sense
that they were actively participating in treatment to enhance their disease condition [36].
These factors were not measured in the trials, hence cannot be controlled with the analysis.
Furthermore, remarkable adherence was noted in this systematic review. This finding
should be interpreted with caution since only three studies (i.e., Brinkworth et al. [37], Durrer et al. [38], and Khodabakhshi et al. [40]) reported the results of the dietary compliance,
and in these studies, compliance was self-reported, which may be subject to recall bias,
error and inaccuracy, or social desirability bias [58]. Low adherence to the KD in adult
patients with cancer was reported in a recent systematic review (49%) [25]. Adherence to
the KD requires drastic changes, which could hinder long-term compliance [59]. Indeed,
Augustus et al. [36] presented the case that the KD may not be offered to all patients and
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that being unable to adhere to the KD or struggling to be adapted to it may adversely affect
the QOL and mental health of patients.
Interestingly, in the majority of included studies, adverse events did not greatly differ
between the KD and its comparison. Furthermore, commonly reported side effects with
the KD included fatigue, dizziness, and gastrointestinal symptoms. These effects, mainly
reported in the first weeks of adopting the KD, are attributed to the keto-induction period,
which varies greatly inter-individual [60,61]. Specifically, Augustus et al. [36] reported
a small but distinct gender-based difference in this period, whereby men adapted faster
to the KD as well as an age-based difference, with younger individuals adapting faster
than their older counterparts. The keto-induction period involves a course of immediate
side-effects known as the keto-flu, which coincide with a high level of ketone bodies. These
effects steadily attenuate over time with keto-adaptation (i.e., organ homeostasis to using
ketones as the primary source of energy [60]).
Strengths and Limitations
This was the first study to compile evidence from RCTs on the effect of KD diet on
QOL in adults with chronic diseases. We adopted a sensitive search strategy, followed the
recommended methods for applying the search, selection of studies, data extraction, and
quality assessment as well as best-practices for the reporting of the review [30,31]. Moreover,
when studies were lacking information, original references were retrieved for additional
data on design and results. Finally, the risk of bias of the majority of included studies was
low, except for the allocation concealment and blinding of participants and personnel.
On the other hand, the review is limited by the heterogeneity of included studies,
which complicates the comparisons and the interpretation of the findings, specifically
regarding assessed populations, assessment methods, and study outcomes. Additionally,
some studies lacked information crucial for the interpretation of the results such as baseline
QOL values, adverse events, assessment of ketosis, and proportion of participants with
sustained physiological ketosis throughout the trial. Having such information would have
helped us interpret the findings in a better manner. Moreover, the search, despite being
highly broad and sensitive, might have missed some relevant studies. This limitation is
common to systematic reviews. Other limitations related to being unable to access one
potentially eligible study for full text screening, and excluding additional two studies in
this phase due to lack of information on randomization and unavailability of outcome data
in the published article. We tried to contact the respective authors, without an answer.
Finally, given the heterogeneity of the studies included, meta-analyzing their results was
impossible.
5. Conclusions
In conclusion, the evidence from RCTs investigating the effect of KD on QOL in adults
with chronic disease is inconclusive. The promising effect noted in some included studies,
and the low rates of adverse events and side effects encourage future investigations in this
regard. Hence, additional high-quality, powered trials with long enough follow-up periods,
are warranted to elucidate the effect of the KD on QOL in adults with chronic disease and
explore the optimal diet composition and timing of initiation for optimal outcomes.
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